Guggenheim analyst Glen Santangelo assumed coverage of CVS Health with a Buy rating and $63 price target, lowered from a previous price target of $85. The analyst is "excited about the strategic repositioning of the company and the long-term opportunities for the new model," but noted that he "underestimated the structural and integration issues facing the business." That said, Santangelo believes that much of the damage to the stock is already done, and believes CVS Health is a good fit for long-term investors that can handle near-term volatility.